If you have a loved one or friend who has Alzheimer’s disease you may be interested in a brand-new cutting edge clinical study being conducted by Athira Pharma. Athira is a biopharmaceutical company focused on developing therapies to restore neuronal health and stop neurodegeneration. The company’s goal is to alter the course of neurological diseases and dementias, such as Alzheimer’s, so that patients can regain their memories, lives and family relationships.
For the past several years, we at Answers for Elders have been watching the developments and achievements that are being made to fight the disease. We do believe that a cure is on the horizon, and we’re grateful to organizations like Athira who are making breakthroughs toward that cure! If your friend or loved one meets the criteria, they could benefit from a study of this kind.
On Answers for Elders Radio, we interviewed Dr. Hans Moebius, Chief Medical Officer of Athira Pharma, as he discussed Athira’s innovative regenerative approach to Alzheimer’s disease focused on promoting the body’s natural repair systems.
>
A key leader in the neurology field for decades, Dr. Moebius discusses the historical landscape of Alzheimer’s disease therapies, and highlights Athira’s innovative and novel approach. This approach has broader therapeutic potential to address multiple dementias, including Parkinson’s disease and many other central nervous system disorders.
Now Enrolling
Athira has two late-stage clinical trials available for Alzheimer’s patients with mild to moderate Alzheimer’s disease in many locations all across the United States and Australia. Those interested in learning more, are encouraged to visit athiraclinicaltrials.com. Related expenses to trial participation are paid for by Athira Pharma and are at no cost to study participants.
The Athira team is motivated and passionate towards making a positive impact on human health. To learn more about the company, visit athira.com.
To learn more about their Alzheimer’s clinical trials visit www.athiraclinicaltrials.com.
